Publications by authors named "T Newsom-Davis"
Article Synopsis
- Second-line treatment for small-cell lung cancer (SCLC) typically depends on how long it's been since the last platinum therapy, with carboplatin and etoposide showing better results if the interval is over 90 days, but this study looks at its effectiveness post-chemo-immunotherapy.
- A retrospective review of 93 patients who received this rechallenge after initial chemo-immunotherapy revealed a 59.1% overall response rate, with a median progression-free survival of 5 months and overall survival of 7 months.
- The findings indicate that carboplatin and etoposide remain a valid second-line option for extensive-stage SCLC, providing consistent outcomes regardless of the platinum-free interval as long as it exceeds
Background: Pneumonitis is a well-described, potentially disabling, or fatal adverse effect associated with both immune checkpoint inhibitors (ICI) and thoracic radiotherapy. Accurate differentiation between checkpoint inhibitor pneumonitis (CIP) radiation pneumonitis (RP), and infective pneumonitis (IP) is crucial for swift, appropriate, and tailored management to achieve optimal patient outcomes. However, correct diagnosis is often challenging, owing to overlapping clinical presentations and radiological patterns.
View Article and Find Full Text PDFArticle Synopsis
- The study compares the effectiveness of atezolizumab plus cabozantinib versus docetaxel in patients with advanced non-small cell lung cancer (NSCLC) who did not respond to prior immunotherapy and chemotherapy.
- Results showed similar overall survival rates: 10.7 months for the combination treatment and 10.5 months for docetaxel, with both showing comparable median progression-free survival.
- Adverse events were reported in both treatment groups; however, a higher percentage of serious adverse events occurred in those receiving atezolizumab plus cabozantinib compared to docetaxel.
Introduction: Lung cancer is the most common cause of cancer death worldwide and most patients present with extensive disease. One-year survival is improving but remains low (37%) despite novel systemic anti-cancer treatments forming the current standard of care. Although new therapies improve survival, most patients have residual disease after treatment, and little is known on how best to manage it.
View Article and Find Full Text PDFPrevious immune checkpoint inhibitor therapy is associated with decreased COVID-19-related hospitalizations and complications in patients with cancer: Results of a propensity-matched analysis of the OnCovid registry.
Int J Infect Dis
February 2024
Objectives: To date, studies have not provided definitive answers regarding whether previous immune checkpoint inhibitor (ICI) treatment alters outcomes for cancer patients with COVID-19.
Methods: The OnCovid registry (NCT04393974) was searched from February 27, 2020, to January 31, 2022, for patients who received systemic anti-cancer therapy in the 4 weeks before laboratory-confirmed COVID-19 diagnosis. Propensity-score matching using country, vaccination status, primary tumor type, sex, age, comorbidity burden, tumor stage, and remission status investigated differences in predefined clinical outcomes comparing those who had or had not received ICIs.